These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 31469834)

  • 1. Leishmaniasis and tumor necrosis factor alpha antagonists in the Mediterranean basin. A switch in clinical expression.
    Bosch-Nicolau P; Ubals M; Salvador F; Sánchez-Montalvá A; Aparicio G; Erra A; Martinez de Salazar P; Sulleiro E; Molina I
    PLoS Negl Trop Dis; 2019 Aug; 13(8):e0007708. PubMed ID: 31469834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor necrosis factor alpha antagonist drugs and leishmaniasis in Europe.
    Zanger P; Kötter I; Kremsner PG; Gabrysch S
    Clin Microbiol Infect; 2012 Jul; 18(7):670-6. PubMed ID: 21985586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histoplasmosis complicating tumor necrosis factor-α blocker therapy: a retrospective analysis of 98 cases.
    Vergidis P; Avery RK; Wheat LJ; Dotson JL; Assi MA; Antoun SA; Hamoud KA; Burdette SD; Freifeld AG; McKinsey DS; Money ME; Myint T; Andes DR; Hoey CA; Kaul DA; Dickter JK; Liebers DE; Miller RA; Muth WE; Prakash V; Steiner FT; Walker RC; Hage CA
    Clin Infect Dis; 2015 Aug; 61(3):409-17. PubMed ID: 25870331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Tolerance of Anti-Tumor Necrosis Factor α Agents in Cutaneous Sarcoidosis: A French Study of 46 Cases.
    Heidelberger V; Ingen-Housz-Oro S; Marquet A; Mahevas M; Bessis D; Bouillet L; Caux F; Chapelon-Abric C; Debarbieux S; Delaporte E; Duval-Modeste AB; Fain O; Joly P; Marchand-Adam S; Monfort JB; Noël N; Passeron T; Ruivard M; Sarrot-Reynauld F; Verrot D; Bouvry D; Fardet L; Chosidow O; Sève P; Valeyre D
    JAMA Dermatol; 2017 Jul; 153(7):681-685. PubMed ID: 28564695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mediterranean leishmaniasis in HIV-infected patients: epidemiological, clinical, and diagnostic features of 22 cases.
    Agostoni C; Dorigoni N; Malfitano A; Caggese L; Marchetti G; Corona S; Gatti S; Scaglia M
    Infection; 1998; 26(2):93-9. PubMed ID: 9561378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-tumour necrosis factor-induced visceral and cutaneous leishmaniasis: case report and review of the literature.
    Català A; Roé E; Dalmau J; Pomar V; Muñoz C; Yelamos O; Puig L
    Dermatology; 2015; 230(3):204-7. PubMed ID: 25633623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relapsing cutaneous leishmaniasis in a patient requiring TNF-α-inhibitor Infliximab for Takayasu-arteritis: Case report and review of the literature.
    Heinemann M; Omansen TF; Hennigs A; Völker K; Menz A; Addo MM; Schmiedel S
    Travel Med Infect Dis; 2020; 37():101700. PubMed ID: 32339673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolution of cutaneous leishmaniasis in the last 30 years in a tertiary hospital of the European Mediterranean coast.
    Marcoval J; Penín RM
    Int J Dermatol; 2017 Jul; 56(7):750-753. PubMed ID: 28247922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leishmaniasis in Malta and the Mediterranean basin.
    Fenech FF
    Ann Trop Med Parasitol; 1997 Oct; 91(7):747-53. PubMed ID: 9625930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cutaneous leishmaniasis in a patient receiving infliximab.
    Hernández-Torres A; García-Vázquez E; Frías-Iniesta J; Herrero-Martínez JA; Gómez-Gómez J
    Scand J Infect Dis; 2013 Jul; 45(7):567-9. PubMed ID: 23270475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and emerging medications for the treatment of leishmaniasis.
    Chakravarty J; Sundar S
    Expert Opin Pharmacother; 2019 Jul; 20(10):1251-1265. PubMed ID: 31063412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers.
    Ruyssen-Witrand A; Gossec L; Salliot C; Luc M; Duclos M; Guignard S; Dougados M
    Clin Exp Rheumatol; 2007; 25(3):430-6. PubMed ID: 17631740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma levels of tumor necrosis factor-alpha (TNF-α), TNF-α soluble receptor type 1 (sTNFR I) and IL-22 in human leishmaniasis.
    Nateghi Rostami M; Seyyedan Jasbi E; Khamesipour A; Miramin Mohammadi A
    Trop Biomed; 2015 Sep; 32(3):478-84. PubMed ID: 26695208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on pharmacotherapy for leishmaniasis.
    Sundar S; Chakravarty J
    Expert Opin Pharmacother; 2015 Feb; 16(2):237-52. PubMed ID: 25346016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological characteristics of cutaneous and mucocutaneous leishmaniasis in patients treated with TNF-α inhibitors.
    Palacios-Diaz RD; Sahuquillo-Torralba A; Rocamora-Durán V; Unamuno-Bustos B; Salavert-Lleti M; Santos-Alarcón S; Quintero A; Garcías-Ladaria J; Vila-Payeras A; Martínez-Doménech A; Mateu-Puchades A; Nadal-Lladó C; Botella-Estrada R
    J Dtsch Dermatol Ges; 2023 May; 21(5):473-480. PubMed ID: 37042124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment patterns following discontinuation of adalimumab, etanercept, and infliximab in a US managed care sample.
    Yeaw J; Watson C; Fox KM; Schabert VF; Goodman S; Gandra SR
    Adv Ther; 2014 Apr; 31(4):410-25. PubMed ID: 24604700
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.
    Bonafede M; Fox KM; Watson C; Princic N; Gandra SR
    Adv Ther; 2012 Aug; 29(8):664-74. PubMed ID: 22886712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leishmaniasis: an update of current pharmacotherapy.
    Sundar S; Chakravarty J
    Expert Opin Pharmacother; 2013 Jan; 14(1):53-63. PubMed ID: 23256501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Leishmaniasis in rheumatoid arthritis].
    Pizzorni C; Secchi ME; Cutolo M
    Reumatismo; 2007; 59(3):235-9. PubMed ID: 17898884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.